SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Sadot Group, Inc. operates as a restaurant chain business. It operates through the following segments: Muscle Maker Grill Restaurant, Pokemoto Hawaiian Poke Restaurant, Non-Traditional (Hybrid), SuperFit Foods Meal Prep, and Sadot. The firm offers protein- based meals featuring chicken, seafood, pasta, hamburgers, wraps and flat breads. It also provides salads, protein shakes and fruit smoothies. The company was founded by Rodney C. Silva in 2022 and is headquartered in Burleson, TX.

Sadot Group Inc

SDOT is trending due to increased attention on low float stocks and discussions around potential catalysts. The community is focused on the company's revenue, potential sale of restaurant assets, and its recent move into a Bitcoin treasury strategy. Traders are closely watching for a breakout, with some citing a possible short squeeze and others expressing skepticism.

Veritone, Inc. engages in the provision of artificial intelligence (AI) computing solutions to media and entertainment, government, and legal and compliance industries. It operates through the following segments: Advertising, aiWARE SaaS Solutions, and aiWARE Content Licensing and Media Services. The Advertising segment places advertisements for clients, primarily with radio broadcasters, podcasters and digital media producers. The aiWARE SaaS Solutions segment offers solutions through a combination of its direct sales force and indirect channel partners, such as value-added resellers (VARs), distributors, system integrators, managed services providers, and referral partners. The aiWARE Content Licensing and Media Services segment sells and markets activities relating to its digital content licensing services business through its direct sales force. The company was founded by Chad Edward Steelberg and Ryan S. Steelberg on June 13, 2014 and is headquartered in Denver, CO.

Veritone Inc

Veritone ($VERI) is trending following news of data refinery contract wins with leading hyperscalers, leading to community excitement and after-hours gains. The community highlights the stock's low market cap relative to its revenue, and some are speculating about future partnerships and a potential short squeeze. Some traders are taking profits while many express long-term bullish sentiment on this AI play.

American Battery Technology Co. is a technology company, which engages in the development and marketing of lithium-ion batteries. Its projects include recycling plant, United States Advanced Battery Consortium (USABC), and Tonopah flats. The company was founded on October 6, 2011 and is headquartered in Reno, NV.

American Battery Technology Company

American Battery Technology Company is trending as the stock reaches new highs, driven by the completion of critical environmental studies for its lithium project. The community is buzzing with excitement, speculating on government funding and potential partnerships, while some long-term investors reflect on their multi-year journey with the company. With increasing volume and market attention on domestic lithium supply, many anticipate further gains, comparing it to other high-flying stocks.

Greenwave Technology Solutions, Inc. is an emerging growth company, which engages in recycling ferrous metal. It also recycles nonferrous metals including aluminum, copper, stainless steel, nickel, brass, titanium, lead, alloys, and mixed metal products. The company was founded on April 26, 2013 and is headquartered in Chesapeake, VA.

Greenwave Technology Solutions Inc

GWAV is trending due to renewed interest in metal recycling and potential short squeeze opportunities, with community members debating its long-term value and potential for further gains. The stock's volatile price action and low float are fueling discussions around quick profits and risks associated with potential dilutions. Sympathy plays in related sectors, like cooking oil recycling, are also gaining traction.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending amid excitement surrounding its upcoming Kraken listing on October 15th, with the community speculating on potential price surges and further exchange listings. Discussions are centered on institutional accumulation, staking benefits, and the potential for Zebec to disrupt traditional payroll systems. Some users express optimism for significant gains, while others debate market manipulation and optimal buying strategies.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

United States Antimony Corp is trending as chatter increases around the potential impact of government contracts and rare earth mineral demand. The community is closely watching for news regarding government stakes and grants, while also highlighting the company's unique position as a domestic antimony producer. Some traders are suggesting the stock could reach levels similar to other mining companies due to its importance in defense and technology.

Blaize Holdings, Inc. provides artificial intelligence solutions. It develops hardware computing platforms for augmented reality, drones, and automobiles. The company was founded by Dinakar C. Munagala, Satyaki Koneru, and Ke Yin in January 2010 and is headquartered in El Dorado Hills, CA.

Blaize Holdings Inc.

Blaize

BZAI is trending as investors discuss a potential upcoming contract announcement, speculating it could drive the stock price higher; some community members believe the stock is undervalued compared to its peers in the edge AI sector. Chatter revolves around its growth potential, with contracted revenues and strategic partnerships in Asia, though concerns about cash runway and potential dilution are also present. Some investors are closely monitoring the stock's technical indicators, anticipating a breakout.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending as investors digest recent news of increased competition in the AI chip space, particularly AMD's deal with OpenAI, sparking discussions about NVIDIA's dominance and potential impact on its valuation. Community members are weighing the significance of these developments, analyzing potential support levels, and speculating on future price movements. Broader market concerns, geopolitical tensions, and upcoming earnings are also contributing to the conversation surrounding the stock.

Astera Labs, Inc. is a global semiconductor company, which engages in the provision of hardware and software solutions for AI and cloud infrastructure applications to solve data, memory, and networking bottlenecks. It operates through the following geographical segments: Taiwan, China, United States, and Other. The company was founded by Jitendra Mohan, Casey Morrison, and Sanjay Gajendra in October 2017 and headquartered in San Jose, CA.

Astera Labs Inc.

Astera Labs Inc

Astera Labs is trending due to a significant price drop, sparking debates about its valuation and potential recovery. Community discussions revolve around competitor announcements and partnerships potentially impacting ALAB's market position in AI infrastructure, while some investors see the dip as a buying opportunity, anticipating a bounce before upcoming earnings. Overall, the stock's volatility and competitive landscape are key focal points.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is trending as investors discuss its AI initiatives, including the rollout of its AI agent Sparky, and its potential impact on customer experience and operational efficiency. The community is also analyzing the stock's valuation relative to peers and anticipating a breakout to new all-time highs. Bullish sentiment is noted amid discussions of strong fundamentals and potential for continued growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Indian equity markets ended higher, with the Nifty index closing below 25,300, led by buying in real estate, pharma, and PSU banks. Metals and technology were the only indices to end in the red on Friday. Renewed optimism over a potential India–US trade deal before the November deadline, along with easing geopolitical tensions in the Middle East, aided investor sentiment.Benchmarks ended higher for the second straight week, gaining over 1.5% and seeing their biggest weekly gains in three months.&nbsp;On Friday, the Sensex closed 1098 points higher at 82,500, while the&nbsp;<a href="https://stocktwits.com/symbol/NIFTY50.NSE">Nifty 50</a> ended up 103 points at 25,285. Broader markets mirrored the gains, with the Nifty Midcap index rising 0.4% and the Smallcap index gaining 0.6%.The retail investor sentiment surrounding the Nifty 50 remained ‘bullish’ by market close on Stocktwits.<figure class="image"><img style="aspect-ratio:804/97;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_10_154349_png_b11c534be4.webp" alt="Screenshot 2025-10-10 154349.png" width="804" height="97"><figcaption>Nifty sentiment and message volume on Oct 10 as of 4:10 pm IST. | source: Stocktwits</figcaption></figure>Stock MovesTCS was among the top Nifty losers, shedding 1% despite steady performance in the September quarter (Q2) earnings. Tata Communications surged 10% on a sentiment boost as TCS unveiled ambitious AI plans that included setting up a 1 GW data centre in India.&nbsp;Weak Q2 performance dragged Tata Elxsi 3% lower.&nbsp;Pharma stocks such as&nbsp;Divi’s Labs, Piramal Pharma, and Wockhardt gained between 3% and 5% after the US Senate passed the National Defense Authorisation Act (NDAA), which includes an amended version of the Biosecure Act.&nbsp; The legislation seeks to protect American biotech and health data from potential foreign threats, especially from Chinese firms.&nbsp;Textile stocks such as Gokaldas, Indo Count surged over 5% on&nbsp;news reports that India-UK are likely to double trade by 2030Man Industries surged 4% after the Securities Appellate Tribunal (SAT) granted a stay on SEBI’s order against the company, which directed it to deposit 50% of the imposed penalty.And new entrant, WeWork India, ended over 2% lower after a muted listing on the bourses.Stock Calls<a href="https://stocktwits.com/Ca_mayankchandel">Mayank Singh Chandel</a> recommended buying&nbsp;<a href="https://stocktwits.com/symbol/LTFOODS.NSE">LT Foods</a>. The stock has found support at a rising trendline and is currently trading just below its 200-day Exponential Moving Average (EMA). In the past, the stock has bounced back from the 200 EMA or slightly below it, demonstrating strong support at this level, which makes the current price a good entry point.&nbsp;He suggested entering at the current market price with a stop loss below ₹375. Short-term price target is set at ₹420, with a medium-term target at ₹500.<stembedurl>https://stocktwits.com/Ca_mayankchandel/message/631777420</stembedurl><a href="https://stocktwits.com/investkaps">Kapil Aggarwal of InvestKaps</a> recommended buying AMAL at the current price of ₹950-₹1,000 for a target of ₹1,200 and a stop loss of ₹900. The stock has seen a healthy, well-channeled correction and taken support around its 20-week EMA. It looks poised for an upmove to a new high.<stembedurl>https://stocktwits.com/investkaps/message/631778299</stembedurl>Markets: What Next?Globally, European markets traded mixed, while US stock futures indicate a subdued start on Wall Street as the US government shutdown is likely to extend into next week.For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

(Photo by Indranil Aditya/NurPhoto via Getty Images)

Indian Markets Extend Gains For Second Week; Nifty Ends Near 25,300, Sensex Surges Over 1,000 Points

Optimism over an India–US trade deal and easing geopolitical tensions boosted investor sentiment. Buying in real estate, pharma, and PSU banks offset weakness in metals and tech stocks.

Equity

Optimism over an India–US trade deal and easing geopolitical tensions boosted investor sentiment. Buying in real estate, pharma, and PSU banks offset weakness in metals and tech stocks.


Shares of Indian contract development and manufacturing (CDMO) companies rose on Friday after the US Senate passed the National Defense Authorisation Act (NDAA), which includes an amended version of the Biosecure Act.The legislation seeks to curb US investments in sensitive Chinese industries and protect American biotech and health data from potential foreign threats, especially from Chinese firms. It also aims to reduce the country’s reliance on overseas laboratories and strengthen domestic biotech security.Following the announcement, the Nifty Pharma index rose 1.56%, led by <a href="https://stocktwits.com/symbol/DIVISLAB.NSE">Divi’s Labs</a>, <a href="https://stocktwits.com/symbol/PPLPHARMA.NSE">Piramal Pharma</a>, and <a href="https://stocktwits.com/symbol/WOCKPHARMA.NSE">Wockhardt</a>, which gained 5%, 4.4%, and 3% each, respectively.How Does It Help Indian Companies?According to brokerage notes, the move could benefit Indian pharma players such as Divi’s Laboratories, Syngene International, Jubilant Pharmova, and Neuland Labs, as global companies look to reduce dependency on China.India already hosts the largest number of USFDA-approved manufacturing plants outside the United States, and pharmaceutical imports from India have grown from $6 million in 2000 to $11 billion in 2023.Analysts believe the Biosecure Act will accelerate this trend over the next decade, supported by an eight-year grandfathering clause that allows US companies time to transition from Chinese suppliers.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Financial market volatility on digital interface with fluctuating trading data real-time stock market analysis and investment trends. (Stock picture/Getty Images)

US Biosecure Act Boosts Indian Pharma: CDMO Stocks Gained Upto 5%

The legislation seeks to protect American biotech and health data from potential foreign threats, especially from Chinese firms

Healthcare stocks in India fell on Friday as investors weighed the impact of U.S. President Donald Trump’s move to impose a 100% tariff on branded and patented drugs starting Oct. 1.&nbsp;The measure, announced in late-night Truth Social posts, exempts only those manufacturers with U.S. plants that are already under construction or have broken ground.The Nifty Healthcare index fell 1.2% on Thursday, with 18 of its 20 components trading lower.&nbsp;IPCA Laboratories remained unchanged, while Torrent Pharma rose 0.01%.Analyst ViewSEBI-registered analyst&nbsp;<a href="https://stocktwits.com/ra_vishaltrehan">Vishal Trehan</a> said Gland Pharma is the most exposed, given its lack of a U.S. manufacturing footprint and reliance on branded or patented formulations.&nbsp;<stembedurl>https://stocktwits.com/ra_vishaltrehan/message/630078378</stembedurl>He noted that Syngene International, Piramal Pharma, and Zydus Lifesciences stand to benefit from their contract manufacturing models and biologics portfolios, which are less tariff-sensitive.Trehan also pointed out that companies with a large branded generics or biosimilars presence, such as Dr. Reddy’s Laboratories and Biocon, will need to accelerate U.S. production to avoid margin erosion.Trump’s Pharma TariffsThe announcement builds on Trump’s escalating trade measures aimed at repatriating drug manufacturing. Last month, he outlined a phased plan, beginning with a “small tariff” on imported drugs, before lifting duties to 150% within 18 months and ultimately to 250%.&nbsp;Pharmaceuticals had earlier been excluded from his reciprocal tariff program, but the new rules extend to prescription medicines, biologics, specialty drugs, and over-the-counter products, with generic drugs remaining exempt.What Is The Retail Mood?On Stocktwits, retail sentiment for Piramal Pharma, Zydus Lifesciences, and Dr. Reddy’s Laboratories was ‘bearish’ amid ‘normal’ message volume.So far this year,&nbsp;<a href="https://stocktwits.com/symbol/GLAND.NSE">Gland Pharma</a> has risen 6.5%, while&nbsp;<a href="https://stocktwits.com/symbol/SYNGENE.NSE">Syngene International</a> is down 29.1%,&nbsp;<a href="https://stocktwits.com/symbol/PPLPHARMA.NSE">Piramal Pharma</a> has slipped 25.9%,&nbsp;<a href="https://stocktwits.com/symbol/ZYDUSLIFE.NSE">Zydus Lifesciences</a> is up 1.8%,&nbsp;<a href="https://stocktwits.com/symbol/DRREDDY.NSE">Dr. Reddy’s Laboratories</a> is down 7.2%, and&nbsp;<a href="https://stocktwits.com/symbol/BIOCON.NSE">Biocon</a> has fallen 6.3%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

India’s Healthcare Index Sinks After Trump’s Pharma Tariff Blow — SEBI Analyst Sees Risks For Gland, Biocon, Dr. Reddy’s

The analyst noted that Syngene, Piramal Pharma, and Zydus Lifesciences may be better positioned, as their contract manufacturing models and biologics portfolios are less susceptible to the tariff impact.

Investors are watching KEI Industries, Polycab India, Piramal Pharma, Hindustan Construction, Geojit Financial, and Park Hotels for upside, provided key support levels hold and volumes confirm momentum.SEBI-registered analyst&nbsp;<a href="https://stocktwits.com/financialsarthis">Financial Sarthis</a> and <a href="https://stocktwits.com/Vinaytaparia">Vinay Taparia</a> have flagged these stocks for potential rallies ahead, showing strong setups with clear breakout levels.Let’s take a look at their stock recommendations:&nbsp;KEI Industries&nbsp;&nbsp;Financial Sarthis picked&nbsp;<a href="https://stocktwits.com/symbol/KEI.NSE">KEI Industries</a> as the stock is currently attempting a breakout after consolidation. If the stock moves past ₹4,200 decisively, it would confirm the breakout, but it needs strong volume support for validation. The stock indicates a potential upside within the range of ₹4,185 to ₹4,235, while immediate support lies near ₹3,800.Polycab India&nbsp;&nbsp;For&nbsp;<a href="https://stocktwits.com/symbol/POLYCAB.NSE">Polycab,&nbsp;</a>Financial Sarthis noted signs of a consolidation breakout. The stock is watching for strength above the ₹7,200 level, where rise in volumes will be crucial in sustaining momentum. If the breakout holds, the upside potential extends towards ₹7,400.<stembedurl>https://stocktwits.com/financialsarthis/message/627328186</stembedurl>Piramal Pharma (PPL Pharma)Vinay Taparia noted a good breakout in&nbsp;<a href="https://stocktwits.com/symbol/PPLPHARMA.NSE">PPL Pharma</a> with good volumes after forming positive divergence in its Relative Strength Index (RSI). The stock can move to ₹218-₹238 level in the next 6 months, with ₹190 level acting as a strong support. But a close below ₹184 negates this view.<stembedurl>https://stocktwits.com/Vinaytaparia/message/627437154</stembedurl>Hindustan Construction (HCC)Taparia also flagged a breakout in&nbsp;<a href="https://stocktwits.com/symbol/HCC.NSE">HCC</a> with good volumes. The stock can move to ₹35-₹38 level in the next 6 to 9 months, but a close below ₹24 negates this view.<stembedurl>https://stocktwits.com/Vinaytaparia/message/627437377</stembedurl>Geojit Financial Services&nbsp;<a href="https://stocktwits.com/symbol/GEOJITFSL.NSE">Geojit</a> is another stock that saw a good breakout with huge volumes, said Taparia. The stock can move to the ₹96 level in the next six to nine months, with a close below ₹70 invalidating the view.<stembedurl>https://stocktwits.com/Vinaytaparia/message/627437706</stembedurl>Park HotelsAnd lastly, Taparia noted the breakout in&nbsp;<a href="https://stocktwits.com/symbol/PARKHOTELS.NSE">Park Hotels</a>. He stated that the stock can potentially move to ₹175-₹190 levels within the next six to nine months. A close below ₹140 negates this view.<stembedurl>https://stocktwits.com/Vinaytaparia/message/627437958</stembedurl>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Piramal Pharma, KEI, HCC, Geojit Financial Among Top Picks On SEBI Analysts’ Radar

Analysts see Polycab and Park Hotels showing promising momentum.

Piramal Pharma (PPL Pharma) shares surged 8% on Wednesday on the back of a positive brokerage note. JM Financial raised its earnings per share estimates for FY27 and FY28, assigning a 'Buy' rating to the stock and a revised target price of ₹313.&nbsp;The company’s contract development and manufacturing organisation arm, Piramal Pharma Solutions (PPS), recently announced a multimillion-dollar investment in collaboration with NewAmsterdam Pharma. The project is estimated to bring $50-100 million in annual revenue for the first three years, providing a robust boost to the company’s financial health.According to JM Financial, the new suite enhances Piramal’s global Oral Solid Dosage (OSD) capabilities and reinforces its long-term growth visibility. They have hiked the EBITDA forecasts by 4% and 7% for FY27 and FY28.Technical OutlookSEBI-registered&nbsp;<a href="https://stocktwits.com/sameerpande">analyst Sameer Pande</a> noted that on the monthly charts,&nbsp;<a href="https://stocktwits.com/symbol/PPLPHARMA.NSE">PPL Pharma</a> stock had taken support around the ₹170-₹180 levels and was showing positive reversal signs on the supertrend. The stock has also crossed the 20-day Exponential Moving Average (EMA).&nbsp;On its daily charts, PPL Pharma stock was showing a breakout on the supertrend, as well as a breakout on the 20-day EMA. Additionally, its Relative Strength Index (RSI) rose from 40 to 58 in a day, supporting the bullish sentiment.&nbsp;Pande recommended buying PPL Pharma with a stop loss at ₹180 on a closing basis, and a target price of ₹229 to be achieved by the end of October.<stembedurl>https://stocktwits.com/sameerpande/message/627314505</stembedurl>What Is The Retail Mood?Data on Stocktwits shows that retail sentiment turned from ‘neutral’ to ‘bullish’ a day ago on this counter.<figure class="image"><img style="aspect-ratio:815/105;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_03_153618_png_c4431be8e1.webp" alt="Screenshot 2025-09-03 153618.png" width="815" height="105"><figcaption>Piramal Pharma sentiment and message volume on Sep 3 as of 3:30 pm IST. | source: Stocktwits</figcaption></figure>PPL Pharma shares have declined 24% year-to-date (YTD).&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

(Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Bullish Signals For Piramal Pharma: SEBI Analyst Flags Technical Breakout, Sees Over 10% Upside By October 

Technical charts and retail sentiment now indicate bullish momentum.

Several midcap stocks are flashing bullish technical setups, with breakouts backed by volume and strong momentum indicators.SEBI-registered analyst&nbsp;<a href="https://stocktwits.com/Vinaytaparia">Vinay Kumar Taparia</a> has identified HEG, DMCC, PPL Pharma, and Precision Wires as stocks to watch based on recent price action and RSI strength.HEG&nbsp;Taparia noted the stock has bounced off an upward trendline and broken out with a bullish candle on above-average volume.&nbsp;<stembedurl>https://stocktwits.com/Vinaytaparia/message/620884241</stembedurl>He expects&nbsp;<a href="https://stocktwits.com/symbol/HEG.NSE">HEG</a> to climb to ₹650 within a year. The stock can be bought at the current market price (CMP) and on dips to ₹510. Exit on a close below ₹490.DMCCAccording to Taparia,&nbsp;<a href="https://stocktwits.com/symbol/DMCC.NSE">DMCC</a> has broken out from a consolidation zone at lower levels with supporting volume.&nbsp;<stembedurl>https://stocktwits.com/Vinaytaparia/message/620880825</stembedurl>He recommends buying at the current market price (CMP) and at ₹260 on declines, targeting ₹290–₹305 and ₹340 over 6–9 months. Traders can maintain a stop loss at ₹248 on a closing basis.PPL PharmaThe analyst pointed to a cup-and-handle breakout at lower levels, backed by rising volume and RSI strength.&nbsp;<stembedurl>https://stocktwits.com/Vinaytaparia/message/620885586</stembedurl><a href="https://stocktwits.com/symbol/PPLPHARMA.NSE">PPL Pharma</a> can be accumulated at CMP and around ₹200, aiming for ₹225, ₹240, and ₹250 over 6 months, with a stop-loss of ₹197.Precision Wires&nbsp;Taparia described&nbsp;<a href="https://stocktwits.com/symbol/PRECWIRE.NSE">Precision Wires</a> as a “superb breakout” with strong volumes.&nbsp;<stembedurl>https://stocktwits.com/symbol/PRECWIRE.NSE</stembedurl>He sees entry points at CMP ₹196 and declines to ₹180, with targets of ₹220 and ₹260 over the next year. Stop-loss: ₹172.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Midcap Breakouts: SEBI RA Flags HEG, DMCC, PPL Pharma, Precision Wires For Upside Moves: 

The analyst has highlighted four midcap names showing bullish patterns with strong volume and RSI support.

Trade Spotlight: How should you trade Hero MotoCorp, SBI Card, IOC, Kalyan Jewellers, DOMS, and others on Tuesday?

The market is likely to maintain its upward rally, albeit with consolidation and volatility in the coming sessions. Here are some trading ideas for the near term.

Buy Piramal Pharma; target of Rs 190: ICICI Securities

ICICI Securities is bullish on Piramal Pharma has recommended buy rating on the stock with a target price of Rs 190 in its research report dated May 13, 2024.

Piramal Pharma shares surge to 52-week high on solid Q4 earnings show

Strong growth in Piramal Pharma's CDMO business, which accounts for 65 percent of its total sales, helped the company report solid year-on-year growth on all key parameters.

Hot Stocks: Why you should bet on Fortis Healthcare, Piramal Pharma for the short term

On the higher end, the record-high zone of 22,750-22,800 seems daunting for the bulls and until the Nifty witnesses a decisive breakthrough, the next leg of rally toward the 23,000 mark seems demanding.

Piramal Pharma Ltd. engages in development and manufacturing of pharmaceutical products. It offers skin care, vitamins and nutrition, antacids, analgesics, gastro-intestinal, and baby-care. The company was founded on March 4, 20202 and is headquartered in Mumbai, India.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '25	-0.43	--	--	N/A
Q1 '25	-0.69	--	--	N/A
Q4 '24	1.16	1.08	-7.53%	MISSED
Q1 '24	0.73	--	--	N/A

PPLPHARMA.NSE
Piramal Pharma Limited

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q2 '25

Historical Earnings

Latest PPLPHARMA.NSE News

PPLPHARMA.NSEPiramal Pharma Limited